Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Companies

atai Therapeutics

atai Therapeutics, Inc.

HQ
United States
Status
active
Listing
Private
Current stage
subsidiary within AtaiBeckley group

clinicaltrials.govregistryverified 2026-08-24

Notes on the record

Current sponsor of record for VLS-01 (NCT06524830), ibogaine (NCT05029401) and EMP-01 (NCT06693609). This is the sponsor-name variant to sweep on ClinicalTrials.gov; older variants return zero.

Assets

Registered trials

  • NCT06524830ClinicalTrials.gov

    PHASE2 · Treatment Resistant Depression · RECRUITING · Australia, Canada, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-08-31

Deals

This company is not a party to any row in data/deals.csv.

In the briefing

1 issue tagged ATAI-THERAPEUTICS.